United States Patent 8,327,844: Scope, Claim Coverage, and US Patent Landscape

United States Drug Patent 8,327,844 (claims provided) is centered on a nasal drug delivery method that uses (i) unilateral nostril sealing, (ii) oropharyngeal velum closure, and (iii) a directed driving gas flow that entrains a substance and passes around the posterior nasal septum to exit the contralateral nostril. Dependent claims then layer: dynamic positive nasal airway pressure sufficient to open auditory/sinus tubes; specific pressure thresholds (5, 50, 100, 200 cm H2O); controlled flows (20 L/min minimum; about 1-20 L/min and about 3-15 L/min bands); delivery triggering using pressure-sensitive valves; entrainment via exhalation-driven supply (including impeller-based variants) versus supply actuation independent of exhalation; powder-specific dispersion and anti-agglomeration features; moisture absorption upstream (desiccant or filter as resistor); metered dispensing into a delivery chamber with gradual release; and optional user feedback (visual or audible signals).

At a landscape level, this claim set occupies a technical intersection that other nasal delivery patents often split across different layers: nasal route systems that ensure nasopharyngeal reach, breath-driven or pressure-driven delivery, and drug formulation handling for dry powders. The independent claim 1 (and its reiterated independent-like claim 5) is broad on the core physiology-directed flow path (around posterior nasal septum to other nostril) and on the use of unilateral sealing plus velum closure. The most commercially sticky claim territory tends to concentrate in the dependent pressure/flow limitations and in the exhalation-driven actuation and valve-trigger mechanisms.

What is the core technical scope of US 8,327,844 claims?

Claim 1 architecture (dominant independent)

Claim 1 is a method with three gating sub-systems:

Unilateral nostril sealing to an outlet
- Seals one nostril to prevent gas escape through that nostril.
Oropharyngeal velum closure
- Closes the velum (acts to prevent oral/oropharyngeal escape and route the flow into the nasal airway).
Directed driving gas flow that entrains a substance and exits the other nostril
- Delivers a gas flow “at such a driving pressure” that the gas flows around the posterior margin of the nasal septum and out the other nostril.
- The substance is entrained in that gas flow.
- The gas flow entraining the substance is “provided by actuation of a supply unit device.”

This is a “routing-and-entrainment” claim: it does not require a specific drug composition in claim 1, only that the substance is delivered.

Claim 5 variant (second independent-like block)

Claim 5 recasts the gas entrainment source:

The entraining gas flow is provided by an impeller driven by an exhalation flow of the subject.

This locks in an exhalation-to-impeller mechanical energy conversion architecture while preserving the same physiological flow path.

How broad is the claim coverage across delivery modes and power sources?

The claim set provides multiple alternative power/flow generation paths that broaden infringement risk across different device designs.

Supply actuation pathways

Supply unit actuation (claim 1, 4, 14, 15, 23, 24, 30, 31, 32, 33-38, 39-50)
- Gas flow entraining substance is provided by actuation of a supply unit device.
Exhalation as the driver (claims 2-3, 5, 19, 26-29, 27-28, 29)
- Claim 2: entraining gas flow is separate to the subject’s exhalation flow.
- Claim 3: supply unit actuated by the exhalation flow.
- Claims 19 and 29: entraining gas flow provided by exhalation flow.
Impeller variant driven by exhalation (claim 5)
- Mechanical conversion of exhalation flow to impeller-driven gas flow.

Flow rate control and operating windows

Claim 4: controlling flow rate is added (no explicit threshold in that claim).
Claim 14: minimum at least 20 L/min.
Claims 15-16: “about 1 to 20 L/min” and “about 3 to 15 L/min.”

These create multiple device-configurable “infringement corridors” based on regulator, valve, blower sizing, and flow sensors.

What physiology and pressure limits define the strongest claim leverage?

Several dependent claims create concrete physical performance targets. These typically function as both (i) validity anchors (clear technical boundaries) and (ii) marketing-defined “spec claims” that competitors must meet or avoid.

Dynamic positive nasal airway pressure and magnitude tiers

Claim 6: provides flow resistance to maintain dynamic positive pressure in nasal airway while gas continues exiting the other nostril.
Claim 7: pressure magnitude is sufficient to force open at least one of auditory tubes or sinus tubes.
Claim 9 onward provide numerical thresholds:
- Claim 9: at least 5 cm H2O
- Claim 10: at least 50 cm H2O
- Claim 11: at least 100 cm H2O
- Claim 12: at least 200 cm H2O

Practical coverage implication: claims are drafted to escalate: an accused device that hits 200 cm H2O is within the chain of dependent limitations (5, 50, 100 also). A device that operates below 5 cm H2O avoids these particular sub-claim limitations but may still fall under broader elements of claim 1 that do not require dynamic positive pressure magnitude.

Velum closure via pressure differential maintained by a flow resistor

Claim 26: velum closure is provided by exhalation by the subject.
Claim 27: exhalation through a flow resistor to maintain positive pressure differential between oral cavity and nasal airway sufficient to maintain velum closed.
Claim 28: positive pressure differential of at least about 5 cm H2O.

This creates an additional numeric boundary tied to velum closure.

How are substance handling and formulation features integrated into the claim set?

The claim set extends beyond delivery mechanics into substance presentation, especially for dry powders.

Dry powder handling and anti-agglomeration

Claim 32: substance is a dry powder.
Claims 33-34: major fraction particle size about 1 to 10 μm.
Claim 25: surface properties modified to prevent agglomeration when powder contacts exhalation flow.

Moisture management upstream

Claim 19: moisture-absorbing element upstream of dispersion chamber; powder in dispersion chamber before entrainment in exhalation flow.
Claim 20: moisture-absorbing element is a desiccant.
Claim 21: moisture-absorbing element is a filter.
Claim 22: filter acts as a flow resistor to exhalation flow.

These elements link “dry powder stability” to a specific device architecture (dispersion chamber plus upstream moisture absorption plus airflow resistor behavior).

Liquid droplet variant

Claim 35: substance comprises liquid droplets.
Claims 36: droplets are solution or suspension.
Claims 37-38: particle size distribution major fraction about 1 to 10 μm.

This supports formulation flexibility while keeping aerodynamic particle size claims aligned to the dry powder size range.

What are the drug product intent hooks (indications and content)?

The claims include broad medicament and nasal condition treatment language.

Substance as pharmaceutical and medicament

Claim 50: substance comprises a pharmaceutical.
Claim 39: substance contains a medicament.
Claim 40: medicament is for treatment of a nasal condition.

Indication coverage (nasal therapeutic targets)

Claim 44: nasal inflammation
Claim 45: rhinitis
Claim 46: nasal polyps
Claim 47: hypertrophic adenoids
Claim 48: secretory otitis media
Claim 49: reduced olfaction

Non-drug cleansing/irrigation

Claim 41: cleansing agent for cleansing nasal airway
Claim 42: irrigating agent for irrigating nasal airway
Claim 43: delivery to posterior region of nasal airway

This indication language expands the commercial use cases across therapeutics and non-therapeutic cleansing/irrigation.

What mechanisms control dose timing and delivery termination?

The claim set includes an event-triggered release concept tied to flow or pressure state.

Pressure-sensitive valve triggering

Claim 17: use a pressure-sensitive valve to trigger release when predetermined flow rate achieved.
Claim 18: valve not opened until subject maintains predetermined flow rate; can close when flow rate drops to stop delivery.

This is a strong functional dosing control clause. It is compatible with both powder dispensing and liquid droplet entrainment as long as valve triggering follows the described flow-rate criterion.

Metered dose into delivery chamber with gradual release

Claim 23: metered dose mechanically dispensed into delivery chamber; entraining gas entrains the substance.
Claim 24: after dispensed, substance gradually released from delivery chamber into the gas flow.

This partitions dosing into mechanical metering plus time-controlled release, which can matter for formulation residence time and plume control.

What is the scope around signals and user interface?

Claim 13: visual or audible signal when predetermined pressure achieved in nasal airway.
Claim 30: visual or audible signal on exhalation by the subject.
Claim 31: visual signal comprises movement of a display member into view.

These claims are device-execution hooks likely used for usability and for ensuring correct physiological activation (proper exhalation profile).

How does the claim set translate into infringement-relevant feature clusters?

Below is a feature matrix keyed to the claim dependencies.

Feature cluster	Claim elements	Numeric bounds	Competitive design pressure
Routing around posterior nasal septum	Claim 1/5: flow around posterior margin and out other nostril	none	Requires physiology-aligned jet path; many prior nasal devices only claim nasal inlet delivery, not contralateral posterior routing
Unilateral nostril sealing	Claim 1/5 and all later composition/indication variants rely on it	none	Many devices use noseclips or single-side application; sealing-to-outlet is a differentiator
Velum closure	Claim 1 and variants; Claim 26-28 exhalation-based closure	≥ about 5 cm H2O (oral-nasal ΔP)	Competitors may avoid velum closure by designing different leak/flow patterns
Dynamic positive nasal pressure and tube/sinus opening	Claim 6-8	≥5, 50, 100, 200 cm H2O (nasal dynamic positive)	Highest-spec differentiator; competitors must either match or design around by operating below thresholds
Powering the entraining flow	Claim 1 supply actuation; Claim 3 exhalation actuates supply; Claim 5 impeller driven by exhalation; Claim 19-22 exhalation entrains	none	Attack surface across breath-driven versus device-actuated architectures
Flow rates	Claim 14, 15-16	≥20 L/min; about 1-20 L/min; about 3-15 L/min	Design-around by selecting flow outside bands
Release triggering	Claim 17-18 pressure-sensitive valve tied to predetermined flow rate	predetermined by system	Competitors can attempt to remove valve trigger or change triggering variable
Dry powder particle size and stability	Claim 32-34 and Claim 25	1-10 μm	Limits for powder plume and dispersion; formulation developers must map to spec
Moisture absorption upstream	Claim 19-22 desiccant/filter	none	Moisture control is device-specific and formulation-specific
Chamber metering and gradual release	Claim 23-24	none	Mechanical metering plus staged release is a recognizable device hallmark

What does the US patent landscape likely look like around this claim set?

With the provided claim language, the landscape divides into three technological “adjacent domains” in US practice:

Nasopharyngeal reach and nasal route systems that manage leakage and airflow path
- Patents in this domain typically claim nasal airflow confinement, nasal valve control, nasal adaptors, and systems that position flow for posterior region access (often toward nasopharynx/eustachian tube region).
Breath-driven or pressure-driven nasal delivery devices
- Many devices use exhalation sensing, pressure generation, or flow regulators. The notable differentiator here is the combination of unilateral nostril sealing plus velum closure and a directed flow around the posterior nasal septum to exit the other nostril.
Dry powder formulation and delivery mechanisms
- Particle size selection, anti-agglomeration surface modifications, dispersion chambers, and moisture handling (desiccants, filters with airflow resistance) are commonly split across formulation patents and device patents. Here they are integrated into delivery claims with specific upstream moisture absorbing element and dispersion-before-entrainment architecture.

How 8,327,844 likely positions versus adjacent prior art

Claims 1 and 5 are structured to capture the end-to-end breathing-to-nasal-jet routing concept. That combination is less common than single-side nasal plumes or nebulizer-style nasal delivery.
Claims 6-12 are spec-like and likely not broadly covered by earlier nasal plume systems unless they explicitly address eustachian tube/sinus opening via nasal positive pressure.
Claims 19-22 integrate anti-humidity and airflow resistance behavior into dry powder dispersion. That combination tends to be narrower than generic “dry powder inhaler” patents because the physiology-driven routing and nasal-specific moisture module are both required.

Landscape risk map for competitors

Competitors building around this technology face two main risk categories:

Device mechanic replication risk: nostril sealing, velum closure control, and posterior septum routing are collectively required in all claim variants that include the same independent claim core.
Performance threshold risk: meeting or exceeding the pressure and flow bands in dependent claims can create direct infringement even if the device uses different drug formulations, as long as the mechanical and physiological routing is present.

What claims are the most enforceable “hook” points for enforcement and licensing?

Based on claim structure and where technical differentiation concentrates, the strongest enforcement hooks are:

Posterior nasal septum routing with contralateral exit (claim 1 and claim 5 core)
Dynamic positive nasal airway pressure with tube/sinus opening (claims 6-8) and numerical pressure ladder (5, 50, 100, 200 cm H2O)
Exhalation-driven architecture tied to impeller or actuated supply (claims 3 and 5; plus claims 19 and 29)
Valve-triggered delivery based on predetermined flow (claims 17-18)
Dry powder integration with dispersion chamber, moisture absorbing element, particle size range, and anti-agglomeration surface properties (claims 19-22, 25, 32-34)

These reflect both system-level novelty (routing, velum control, pressure generation) and product-level alignment (dry powder handling and dosing control).

Key Takeaways

US 8,327,844 claims a nasal delivery method that combines unilateral nostril sealing, oropharyngeal velum closure, and a driving gas flow entraining a substance that passes around the posterior nasal septum and exits the other nostril (claim 1; claim 5 impeller driven by exhalation).
The commercial risk concentrates in dependent performance limitations: dynamic positive nasal airway pressure with numeric thresholds (≥5, ≥50, ≥100, ≥200 cm H2O) and functional outcome hooks (auditory tube/sinus opening).
The most device-specific claim terrain includes exhalation-driven supply/impeller, flow resistance maintaining positive pressure, and pressure-sensitive valve triggering.
For drug developers, enforcement can extend through dry powder formulation handling: 1-10 μm major fraction, upstream moisture absorption (desiccant or filter functioning as a resistor), and anti-agglomeration surface modification.
Indication language is broad across nasal disorders (rhinitis, nasal polyps, hypertrophic adenoids, secretory otitis media, reduced olfaction) and also supports cleansing/irrigation uses.

FAQs

1) What does the patent require, at minimum, for claim 1 coverage?

Unilateral nostril sealing to an outlet, velum closure, and a driving gas flow entraining a substance that travels around the posterior nasal septum and exits the other nostril, with the entraining flow provided by a actuated supply unit device.

2) How do the dependent claims narrow the breathing and power-source implementation?

They specify either supply actuation based on the subject’s exhalation flow, or entrainment provided by the exhalation flow itself, including an impeller driven by exhalation.

3) Which claims create the clearest “design-around” numeric targets?

Dynamic positive nasal airway pressure thresholds (≥5, ≥50, ≥100, ≥200 cm H2O), and velum-maintaining oral-to-nasal pressure differential (at least about 5 cm H2O). Flow-rate bands (≥20 L/min; about 1-20 L/min; about 3-15 L/min) are also numeric.

4) Does the patent cover both dry powder and liquids?

Yes. Dry powder is explicitly covered with particle size distribution limits, and liquid droplets are covered with similar particle size distribution language.

5) What is the dosing control mechanism described?

A pressure-sensitive valve triggers release when a predetermined flow rate is achieved, and the valve can close when flow rate drops below that threshold; separate claims also describe metered mechanical dispensing into a delivery chamber with gradual release.

References

[1] United States Patent No. 8,327,844. Claims as provided in the prompt.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9904906.6	Mar 3, 1999
United Kingdom	9911686.5	May 19, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	285810	⤷ Start Trial
Austria	422923	⤷ Start Trial
Austria	427130	⤷ Start Trial
Austria	487506	⤷ Start Trial
Austria	506983	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,327,844